U.S. markets open in 2 hours 46 minutes
  • S&P Futures

    4,462.75
    -11.50 (-0.26%)
     
  • Dow Futures

    34,679.00
    -70.00 (-0.20%)
     
  • Nasdaq Futures

    15,480.25
    -37.50 (-0.24%)
     
  • Russell 2000 Futures

    2,218.80
    -9.10 (-0.41%)
     
  • Crude Oil

    72.12
    -0.49 (-0.67%)
     
  • Gold

    1,764.20
    +7.50 (+0.43%)
     
  • Silver

    23.03
    +0.24 (+1.04%)
     
  • EUR/USD

    1.1786
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    19.37
    +1.19 (+6.55%)
     
  • GBP/USD

    1.3793
    -0.0004 (-0.03%)
     
  • USD/JPY

    109.9610
    +0.2430 (+0.22%)
     
  • BTC-USD

    47,475.29
    -397.84 (-0.83%)
     
  • CMC Crypto 200

    1,205.60
    -27.69 (-2.25%)
     
  • FTSE 100

    7,015.58
    -11.90 (-0.17%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Novartis to answer U.S. Senate demand for data manipulation details

  • Oops!
    Something went wrong.
    Please try again later.
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ZURICH (Reuters) - Novartis <NOVN.S> plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.

"We are planning to respond but we haven't submitted yet," a spokesman said on Monday.

U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.

Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.

(Reporting by John Miller)